VEGFA and neoplasm: In colorectal cancer, miR-1249-3p may present as a novel therapeutic candidate based on its inhibitory actions in tumor growth, metastasis, and angiogenesis by targeting vascular endothelial growth factor A (VEGFA) and high mobility group AT-hook 2 (HMGA2) [34].